These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 17620824)
61. Screening for abacavir hypersensitivity. Deresinski S AIDS Alert; 2007 Dec; 22(12):140-1. PubMed ID: 18411482 [No Abstract] [Full Text] [Related]
62. Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome. Llano A; Brander C Cell Res; 2012 Dec; 22(12):1637-9. PubMed ID: 22777424 [TBL] [Abstract][Full Text] [Related]
63. Exuberant Positive Patch Test to Abacavir in a Patient with the HLA-B*5701 Haplotype. Micozzi S; Rojas P; Rodriguez-Gamboa A; De Barrio M J Allergy Clin Immunol Pract; 2015; 3(6):965-7. PubMed ID: 26116952 [No Abstract] [Full Text] [Related]
64. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example. Hughes AR; Brothers CH; Mosteller M; Spreen WR; Burns DK Pharmacogenomics; 2009 Feb; 10(2):225-33. PubMed ID: 19207023 [TBL] [Abstract][Full Text] [Related]
65. Abacavir pharmacogenetics--from initial reports to standard of care. Martin MA; Kroetz DL Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914 [TBL] [Abstract][Full Text] [Related]
66. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Hughes DA; Vilar FJ; Ward CC; Alfirevic A; Park BK; Pirmohamed M Pharmacogenetics; 2004 Jun; 14(6):335-42. PubMed ID: 15247625 [TBL] [Abstract][Full Text] [Related]
67. The association of opportunistic infections with the occurrence of trimethoprim/sulfamethoxazole hypersensitivity in patients infected with human immunodeficiency virus. Lehmann DF; Liu A; Newman N; Blair DC J Clin Pharmacol; 1999 May; 39(5):533-7. PubMed ID: 10234602 [TBL] [Abstract][Full Text] [Related]
68. Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients? Brothers C; Cutrell A; Scott T; Hernandez J; Moult A Int J Clin Pract; 2006 May; 60(5):611-2; author reply 612. PubMed ID: 16700867 [No Abstract] [Full Text] [Related]
69. Understanding drug hypersensitivity: what to look for when prescribing abacavir. Hetherington S AIDS Read; 2001 Dec; 11(12):620-2. PubMed ID: 11806176 [TBL] [Abstract][Full Text] [Related]
70. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir. Agbaji OO; Akanbi MO; Otoh I; Agaba PA; Akinsola R; Okolie V; Ugoagwu PO; Babadoko AA; Adediran A; Finomo FO; Abah JO; Muktar HM; Akanmu AS Niger Postgrad Med J; 2019; 26(4):195-198. PubMed ID: 31621657 [TBL] [Abstract][Full Text] [Related]
71. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Hughes S; Hughes A; Brothers C; Spreen W; Thorborn D; Pharm Stat; 2008; 7(2):121-9. PubMed ID: 17534855 [TBL] [Abstract][Full Text] [Related]
72. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review. Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250 [TBL] [Abstract][Full Text] [Related]
73. Abacavir hypersensitivity. Abel S; Paturel L; Cabié A N Engl J Med; 2008 Jun; 358(23):2515; author reply 2515-6. PubMed ID: 18536095 [No Abstract] [Full Text] [Related]
74. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367 [TBL] [Abstract][Full Text] [Related]